Dashboard
Manage Tickers

VNDA Vanda Pharmaceuticals Inc.

Nasdaq vandapharma.com


$ 4.85 $ -0.35 (-6.74 %)    

Thursday, 20-Nov-2025 15:49:34 EST
CLICK TO SEE RELEVANT LITIGATION UPDATES
QQQ $ 586.47 $ -25.20 (-4.12 %)
DIA $ 458.69 $ -7.99 (-1.71 %)
SPY $ 653.53 $ -19.45 (-2.88 %)
TLT $ 89.28 $ 0.29 (0.33 %)
GLD $ 375.05 $ -0.18 (-0.05 %)
$ 5.14
$ 5.19
$ 4.84 x 5,818
$ 4.85 x 922
$ 4.84 - $ 5.22
$ 3.81 - $ 5.70
1,780,583
na
303.76M
$ 0.57
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 10-30-2025 09-30-2025 10-Q
2 07-31-2025 06-30-2025 10-Q
3 05-08-2025 03-31-2025 10-Q
4 02-14-2025 12-31-2024 10-K
5 11-07-2024 09-30-2024 10-Q
6 08-01-2024 06-30-2024 10-Q
7 05-09-2024 03-31-2024 10-Q
8 02-08-2024 12-31-2023 10-K
9 11-09-2023 09-30-2023 10-Q
10 07-28-2023 06-30-2023 10-Q
11 05-03-2023 03-31-2023 10-Q
12 02-09-2023 12-31-2022 10-K
13 11-03-2022 09-30-2022 10-Q
14 08-04-2022 06-30-2022 10-Q
15 05-06-2022 03-31-2022 10-Q
16 02-24-2022 12-31-2021 10-K
17 11-04-2021 09-30-2021 10-Q
18 07-29-2021 06-30-2021 10-Q
19 05-06-2021 03-31-2021 10-Q
20 02-11-2021 12-31-2020 10-K
21 10-29-2020 09-30-2020 10-Q
22 08-06-2020 06-30-2020 10-Q
23 05-07-2020 03-31-2020 10-Q
24 02-26-2020 12-31-2019 10-K
25 11-07-2019 09-30-2019 10-Q
26 08-01-2019 06-30-2019 10-Q
27 05-03-2019 03-31-2019 10-Q
28 02-19-2019 12-31-2018 10-K
29 11-07-2018 09-30-2018 10-Q
30 08-02-2018 06-30-2018 10-Q
31 05-02-2018 03-31-2018 10-Q
32 02-15-2018 12-31-2017 10-K
33 11-08-2017 09-30-2017 10-Q
34 08-03-2017 06-30-2017 10-Q
35 05-03-2017 03-31-2017 10-Q
36 02-17-2017 12-31-2016 10-K
37 11-03-2016 09-30-2016 10-Q
38 07-28-2016 06-30-2016 10-Q
39 05-05-2016 03-31-2016 10-Q
40 02-12-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

vanda-reports-big-win-in-wegovy-support-study-analysts-upbeat
Vanda Reports Big Win In Wegovy Support St...
11/20/2025 18:59:18

Vanda's tradipitant cut Wegovy-related vomiting by 50% in a new trial, prompting bullish analyst views and price targets.

hc-wainwright--co-reiterates-buy-on-vanda-pharmaceuticals-maintains-20-price-target
HC Wainwright & Co. Reiterates Buy on Vand...
11/19/2025 11:52:28

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Vanda Pharmaceuticals (NASDAQ:VNDA) with a Buy and maintains $...

vanda-pharmaceuticals-option-alert-dec-19-6-calls-at-the-ask-2499--04-vs-572-oi-ref5295
Vanda Pharmaceuticals Option Alert: Dec 19...
11/18/2025 17:24:55

side-effects-from-wegovy-this-vanda-pharmaceuticals-drug-halves-vomiting-in-patients
Side Effects From Wegovy? This Vanda Pharm...
11/18/2025 15:49:29

Vanda Pharmaceuticals' tradipitant successfully reduced Wegovy-induced vomiting by 50% in a clinical trial. Phase 3 anticip...

reported-earlier-vanda-reports-tradipitant-significantly-reduces-glp-1-induced-nausea-and-vomiting-strengthening-role-as-adjunct-in-rapidly-expanding-50b-plus-market
Reported Earlier, Vanda Reports Tradipitan...
11/18/2025 07:21:35

this-docebo-analyst-begins-coverage-on-a-bullish-note-here-are-top-3-initiations-for-wednesday
This Docebo Analyst Begins Coverage On A B...
11/05/2025 13:48:58

this-trex-company-analyst-turns-bearish-here-are-top-5-downgrades-for-wednesday
This Trex Company Analyst Turns Bearish; H...
11/05/2025 12:22:37

b-riley-securities-initiates-coverage-on-vanda-pharmaceuticals-with-buy-rating-announces-price-target-of-11
B. Riley Securities Initiates Coverage On ...
11/05/2025 11:22:03

B. Riley Securities analyst Madison El-Saadi initiates coverage on Vanda Pharmaceuticals (NASDAQ:VNDA) with a Buy rating and...

cantor-fitzgerald-maintains-overweight-on-vanda-pharmaceuticals-lowers-price-target-to-11
Cantor Fitzgerald Maintains Overweight on ...
10/30/2025 13:48:50

Cantor Fitzgerald analyst Olivia Brayer maintains Vanda Pharmaceuticals (NASDAQ:VNDA) with a Overweight and lowers the price...

vanda-pharmaceuticals-narrows-fy2025-sales-guidance-from-210000m-250000m-to-210000m-230000m-vs-224977m-est
Vanda Pharmaceuticals Narrows FY2025 Sales...
10/29/2025 20:02:53

Vanda Pharmaceuticals (NASDAQ:VNDA) narrows FY2025 sales outlook from $210.000 million-$250.000 million to $210.000 million-$23...

vanda-pharma-q3-eps-038-beats-045-estimate-sales-56258m-miss-58733m-estimate
Vanda Pharma Q3 EPS $(0.38) Beats $(0.45) ...
10/29/2025 20:02:22

Vanda Pharma (NASDAQ:VNDA) reported quarterly losses of $(0.38) per share which beat the analyst consensus estimate of $(0.45) ...

earnings-scheduled-for-october-29-2025
Earnings Scheduled For October 29, 2025
10/29/2025 11:11:56

jim-cramer-calls-cameco-a-good-company-recommends-buying-this-financial-stock
Jim Cramer Calls Cameco A Good Company, Re...
10/27/2025 12:05:50

On CNBC's "Mad Money Lightning Round," Jim Cramer discussed Apollo Global, National Fuel Gas, Main Street Capital a...

vanda-pharmaceuticals-agrees-on-a-collaborative-framework-with-the-fda-for-the-resolution-of-certain-disputes-regarding-hetlioz-and-tradipitant
Vanda Pharmaceuticals Agrees On A Collabor...
10/01/2025 21:08:10

Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced that it has agreed on a collaborative framework with the U.S. ...

anaptysbio-charts-path-to-split-into-two-public-companies-by-2026
AnaptysBio Charts Path To Split Into Two P...
09/30/2025 17:59:14

AnaptysBio plans to separate into Royalty Management Co. and Biopharma Co. by 2026, with each positioned for growth in distinct...

vanda-pharmaceuticals-announced-the-publication-of-an-article-titled-melatonin-agonist-tasimelteon-improves-sleep-in-patients-with-primary-insomnia-a-multicenter-randomized-double-blind-placebo-controlled-trial-in-plos-one-a-leading-open-access-journal
Vanda Pharmaceuticals Announced The Public...
09/25/2025 12:08:08

Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced the publication of an article titled "Melatonin agonist t...

vanda-pharmaceuticals-receives-fda-orphan-drug-designation-for-vgt-1849b-a-peptide-nucleic-acid-based-candidate-in-polycythemia-vera
Vanda Pharmaceuticals Receives FDA Orphan ...
08/28/2025 11:04:43

vanda-pharmaceuticals-asked-martin-makary-to-review-the-decision-made-by-jacqueline-corrigan-curay-the-departing-director-of-the-fdas-center-for-drug-evaluation-and-research-days-before-her-retirement-that-upholds-an-office-of-generic-drugs-decision-to-approve-two-generic-versions-of-hetlioz
Vanda Pharmaceuticals Asked Martin Makary ...
08/21/2025 20:46:16

WASHINGTON, Aug. 21, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced that it has asked Ma...

hc-wainwright--co-reiterates-buy-on-vanda-pharmaceuticals-maintains-20-price-target
HC Wainwright & Co. Reiterates Buy on Vand...
08/21/2025 11:20:35

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Vanda Pharmaceuticals (NASDAQ:VNDA) with a Buy and maintains $...

vanda-wins-major-court-battle-for-jet-lag-drug-forcing-fda-to-revisit-rejection
Vanda Wins Major Court Battle For Jet Lag ...
08/18/2025 11:08:23

Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced that it secured a landmark victory over the U.S. Food and Drug...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION